MENU
IRD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Opus Genetics (IRD) Ownership - Who owns Opus Genetics?

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders... Show more

A.I.Advisor
Nov 12, 2026

What Is Opus Genetics (IRD)? Company Overview, Business Model and Market Position

Key Takeaways

  • IRD is the Nasdaq ticker for Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on gene therapies for inherited retinal diseases (IRDs).
  • The company was formed in October 2024 through the all-stock acquisition of private gene-therapy developer Opus Genetics by Ocuphire Pharma.
  • Its lead candidate, OPGx-LCA5, targets LCA5-related blindness and has advanced into late-stage clinical development.
  • Opus Genetics also holds a broader pipeline of AAV-based gene therapies plus phentolamine ophthalmic solution, which is partnered with Viatris.
  • As an early-stage biotech, the company generates limited revenue and has reported net losses, a common profile for pre-commercial drug developers.

Introduction

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies designed to restore vision and prevent blindness in people with inherited retinal diseases (IRDs) — a group of rare, often progressive genetic disorders that damage the light-sensing retina. The company trades on the Nasdaq under the ticker IRD, an abbreviation that reflects its focus on these conditions. Investors follow the stock primarily for the potential of its gene-therapy pipeline, which targets diseases that currently have few or no approved treatments.

Company Profile and History

Opus Genetics was created in October 2024, when Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company previously listed as OCUP, completed an all-stock acquisition of the privately held Opus Genetics. The combined company adopted the Opus Genetics name and began trading on the Nasdaq under the IRD ticker.

The private Opus Genetics was launched in 2021 by the Retinal Degeneration Fund (RD Fund), the venture investment arm of the Foundation Fighting Blindness. Its scientific founders included Jean Bennett, M.D., Ph.D., of the University of Pennsylvania, a pioneer in ocular gene therapy. The company is headquartered in the Research Triangle area of Durham, North Carolina, and is led by Chief Executive Officer George Magrath, M.D., with Ben Yerxa, Ph.D., serving as president.

Business Model and Pipeline

Like many clinical-stage biotechnology companies, Opus Genetics does not yet have a commercially approved therapy from its gene-therapy programs. Its business model centers on advancing a pipeline of investigational treatments through clinical trials, with revenue historically derived from licensing, collaboration agreements, and milestone payments rather than product sales. The company funds its research and development primarily through cash reserves and financing arrangements.

Opus Genetics' core focus is adeno-associated virus (AAV)-based gene therapy, an approach that uses a modified, non-disease-causing virus to deliver a functional copy of a gene into retinal cells. Its pipeline includes:

  • OPGx-LCA5 — the lead program, targeting Leber congenital amaurosis (LCA) caused by mutations in the LCA5 gene. It has shown early clinical proof-of-concept and has advanced toward late-stage development.
  • OPGx-BEST1 — a therapy for retinal disease caused by mutations in the BEST1 gene, which is being evaluated in a Phase 1/2 trial.
  • Additional preclinical programs — including OPGx-RHO, OPGx-RDH12, OPGx-MERTK, OPGx-NMNAT1, and OPGx-CNGB1, which target other forms of retinitis pigmentosa and related retinal dystrophies.

Beyond gene therapy, the company's portfolio includes phentolamine ophthalmic solution 0.75%, an eye-drop candidate for conditions including presbyopia (age-related near-vision loss) and dim-light vision disturbances. Phentolamine is partnered with VTRS (Viatris) for commercialization in certain indications. The company also holds APX3330, a small-molecule inhibitor under evaluation for non-proliferative diabetic retinopathy.

Why Investors Follow IRD

Investor interest in Opus Genetics centers on the size of the unmet medical need it addresses. Inherited retinal diseases are rare, progressive, and often lead to severe vision loss or blindness, and most lack approved disease-modifying treatments. A successful one-time gene therapy could represent a significant medical advance and a substantial commercial opportunity.

The company's scientific credibility is another draw. Its gene-therapy programs are built on technology licensed from leading academic institutions, and its scientific co-founders include researchers who helped establish the field of ocular gene therapy. Positive early data from the OPGx-LCA5 program — which showed visual improvements in treated patients with late-stage disease — has reinforced the pipeline's potential and supports the company's competitive positioning in the retinal gene-therapy space.

Risks and Important Considerations

Investing in Opus Genetics carries the risks typical of clinical-stage biotechnology. Its therapies must clear multiple clinical-trial phases and secure regulatory approval from agencies such as the U.S. Food and Drug Administration (FDA) before generating meaningful revenue, and there is no guarantee of success. Clinical trials can be delayed, fail to meet their endpoints, or face safety concerns.

The company also faces financial constraints. It has reported net losses as it funds research and development, and its financial profile depends on maintaining sufficient cash to advance its pipeline — a challenge for many pre-revenue biotechs. Competition in the gene-therapy and ophthalmology fields is intensifying, and the company may need to raise additional capital, which can dilute existing shareholders. Rare-disease markets, while underserved, are also small in patient numbers, which can affect long-term commercial potential.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Whether you are researching biotechnology names like IRD or scanning other sectors, the AI Screener offers a structured way to narrow the field and refine your watchlist.

Conclusion

Opus Genetics stands out as a focused player in the emerging field of retinal gene therapy, pursuing treatments for rare inherited diseases that have historically been neglected. Its combination of a late-stage lead candidate, a broader AAV-based pipeline, and an academic pedigree positions it among the companies to watch in ophthalmic genetic medicine. At the same time, its clinical-stage status and ongoing losses mean its long-term value remains tied to the outcomes of clinical trials and regulatory reviews.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Profile

Industry
N/A
Address
8 Davis Drive
Phone
+1 984 884-6030
Employees
28
Web
https://www.opusgtx.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
347.76M
P/E Ratio
-3.24
Total Cash
88.81M
Projected Growth
N/A
Total Debt
36.2M
Revenue
9.86M
Risk (Beta)
0.39
Dividend Yield
N/A
Total Cash/Share
1.07
Total Debt/Equity
N/A
Revenue/Share
0.12 USD as % of share price
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics

Industry Biotechnology

Industry
N/A
Address
8 Davis Drive
Phone
+1 984 884-6030
Employees
28
Web
https://www.opusgtx.com
Who owns Opus Genetics? IRD symbol Ownership - Tickeron.com